Sugi Predict

Sugi Predict / Compounds / SCHEMBL622600

SCHEMBL622600

SCHEMBL622600

CC1CCC(C=O)N1C(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.46
▸ CHRM1 P11229 1/20 0.46
▸ CHRM3 P20309 1/20 0.46
▸ PREP P48147 4/20 0.38
▸ DDB1 Q16531 1/20 0.36
▸ CRBN Q96SW2 1/20 0.36
▸ NR1H2 P55055 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ USP2 O75604 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ CTSK P43235 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ EPHX1 P07099 1/20 0.34
▸ HSD11B1 P28845 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26143938 1.00 CHRM2 (0.46) CHRM2CHRM1CHRM3PREPDDB1
SCHEMBL6126309 1.00 CHRM2 (0.46) CHRM2CHRM1CHRM3PREPDDB1
SCHEMBL220833 1.00 CHRM2 (0.46) CHRM2CHRM1CHRM3PREPDDB1
SCHEMBL26363782 1.00 CHRM2 (0.46) CHRM2CHRM1CHRM3PREPDDB1
SCHEMBL19915056 1.00 CHRM2 (0.46) CHRM2CHRM1CHRM3PREPDDB1
SCHEMBL29102381 1.00 CHRM2 (0.46) CHRM2CHRM1CHRM3PREPDDB1
SCHEMBL3075660 0.90 CHRM2 (0.44) CHRM2CHRM1CHRM3PREPNR1H2
SCHEMBL2690338 0.90 CHRM2 (0.44) CHRM2CHRM1CHRM3PREPNR1H2
SCHEMBL2690340 0.90 CHRM2 (0.44) CHRM2CHRM1CHRM3PREPNR1H2
SCHEMBL3075663 0.90 CHRM2 (0.44) CHRM2CHRM1CHRM3PREPNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116997549-A Pyrrolo [3,2-C ] pyridin-4-one derivatives for the treatment of cancer 蝎子疗法股份有限公司 2023-11-03 — — CN disclosed
US-20210053981-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2021-02-25 — — US disclosed
EP-3778606-A2 CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2021-02-17 — — EP disclosed
US-10807990-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2020-10-20 — — US disclosed
US-10800789-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2020-10-13 — — US disclosed
EP-3699176-A2 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2020-08-26 — — EP disclosed
US-20200123132-A1 ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC 2020-04-23 — — US disclosed
US-20200071337-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2020-03-05 — — US disclosed
US-20190337960-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2019-11-07 — — US disclosed
US-20190276468-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2019-09-12 — — US disclosed
EP-2640719-A2 ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2013-09-25 — — EP disclosed
EP-2635588-A1 CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2013-09-11 — — EP disclosed
US-20130177530-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-07-11 — — US disclosed
US-20130164260-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-06-27 — — US disclosed
US-20130156732-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-06-20 — — US disclosed
EP-2603504-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2013-06-19 — — EP disclosed
WO-2013075029-A1 CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-05-23 — — WO disclosed
US-20120195857-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2012-08-02 — — US disclosed
WO-2012068234-A2 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-05-24 — — WO disclosed
WO-2012021591-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130177530-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 CHRM2 4866/4885CHRM1 4813/4885CHRM3 4743/4885
US-20200071337-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 CHRM2 4866/4885CHRM1 4813/4885CHRM3 4743/4885
US-20120195857-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS CHRM2 4697/4885CHRM1 4713/4885CHRM3 3883/4885
US-20130156732-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 CHRM2 4866/4885CHRM1 4813/4885CHRM3 4743/4885
US-20190276468-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 CHRM2 4866/4885CHRM1 4813/4885CHRM3 4743/4885
US-10807990-B2 Antiviral compounds MAVS, EIF2AK2, SARS1 CHRM2 4866/4885CHRM1 4813/4885CHRM3 4743/4885
US-20130164260-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 CHRM2 4866/4885CHRM1 4813/4885CHRM3 4743/4885
US-20200123132-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 CHRM2 4881/4885CHRM1 4856/4885CHRM3 4838/4885
US-10800789-B2 Antiviral compounds MAVS, EIF2AK2, SARS1 CHRM2 4866/4885CHRM1 4813/4885CHRM3 4743/4885
US-20210053981-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 CHRM2 4866/4885CHRM1 4813/4885CHRM3 4743/4885
US-20190337960-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 CHRM2 4866/4885CHRM1 4813/4885CHRM3 4743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.